Synergistic inhibition of colorectal cancer progression by silencing Aurora A and the targeting protein for Xklp2

Figure 4 Knockdowns of Aurora A and targeting protein for Xklp2 inhibited viability of colorectal cancer cell. A: Relative expression of Aurora kinase A (AURKA) and targeting protein for Xklp2 (TPX2) in NCM460, SW480, HCT116, and LOVO cells; B: After short hairpin RNA of AURKA (sh-AURKA) 1, 2, and 3 plasmids transfection, AURKA mRNA expression was decreased in SW480 and LOVO cells; C: TPX2 mRNA expression was decreased in SW480 and LOVO cells with transfected sh-TPX21, 2, and 3 plasmids. All gene transcript levels were measured by quantitative real time-polymerase chain reaction; D: AURKA; E: TPX2 protein expression levels were decreased in SW480 and LOVO cells with sh-AURKA/TPX21, 2, and 3 plasmids transfection. Western blotting was used to detect relative protein expression. Cell counting kit-8 assay was used to detect cell viability in F: SW480; G: LOVO cells with AURKA and TPX2 knockdown. After 12-, 24-, or 48-hour treatment with transfection, cell viability was inhibited in SW480 and LOVO cells. ¹P < 0.01 vs NCM460 group. ²P < 0.05 vs negative control of short hairpin RNA (sh-NC) group. ³P < 0.01 vs sh-NC group. ⁴P < 0.05 vs short hairpin RNA of AURKA (sh-AURKA) group. ⁵P < 0.01 vs sh-AURKA group. ⁶P < 0.01 vs short hairpin-TPX2 group. qPCR: Quantitative real time-polymerase chain reaction; AURKA: Aurora kinase A; TPX2: Targeting protein for Xklp2; sh-NC: Negative control of short hairpin RNA; sh-AURKA: Short hairpin RNA of Aurora kinase A; sh-TPX2: Short hairpin RNA of targeting protein for Xklp2; OD: Optical density; WB: Western blotting.